Cargando…

Human antibody profiling technologies for autoimmune disease

Autoimmune diseases are caused by the break-down in self-tolerance mechanisms and can result in the generation of autoantibodies specific to human antigens. Human autoantigen profiling technologies such as solid surface arrays and display technologies are powerful high-throughput technologies utilis...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlton, Lauren H., McGregor, Reuben, Moreland, Nicole J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870766/
https://www.ncbi.nlm.nih.gov/pubmed/36690876
http://dx.doi.org/10.1007/s12026-023-09362-8
_version_ 1784877038509752320
author Carlton, Lauren H.
McGregor, Reuben
Moreland, Nicole J.
author_facet Carlton, Lauren H.
McGregor, Reuben
Moreland, Nicole J.
author_sort Carlton, Lauren H.
collection PubMed
description Autoimmune diseases are caused by the break-down in self-tolerance mechanisms and can result in the generation of autoantibodies specific to human antigens. Human autoantigen profiling technologies such as solid surface arrays and display technologies are powerful high-throughput technologies utilised to discover and map novel autoantigens associated with disease. This review compares human autoantigen profiling technologies including the application of these approaches in chronic and post-infectious autoimmune disease. Each technology has advantages and limitations that should be considered when designing new projects to profile autoantibodies. Recent studies that have utilised these technologies across a range of diseases have highlighted marked heterogeneity in autoantibody specificity between individuals as a frequent feature. This individual heterogeneity suggests that epitope spreading maybe an important mechanism in the pathogenesis of autoimmune disease in general and likely contributes to inflammatory tissue damage and symptoms. Studies focused on identifying autoantibody biomarkers for diagnosis should use targeted data analysis to identify the rarer public epitopes and antigens, common between individuals. Thus, utilisation of human autoantigen profiling technology, combined with different analysis approaches, can illuminate both pathogenesis and biomarker discovery.
format Online
Article
Text
id pubmed-9870766
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-98707662023-01-25 Human antibody profiling technologies for autoimmune disease Carlton, Lauren H. McGregor, Reuben Moreland, Nicole J. Immunol Res Review Autoimmune diseases are caused by the break-down in self-tolerance mechanisms and can result in the generation of autoantibodies specific to human antigens. Human autoantigen profiling technologies such as solid surface arrays and display technologies are powerful high-throughput technologies utilised to discover and map novel autoantigens associated with disease. This review compares human autoantigen profiling technologies including the application of these approaches in chronic and post-infectious autoimmune disease. Each technology has advantages and limitations that should be considered when designing new projects to profile autoantibodies. Recent studies that have utilised these technologies across a range of diseases have highlighted marked heterogeneity in autoantibody specificity between individuals as a frequent feature. This individual heterogeneity suggests that epitope spreading maybe an important mechanism in the pathogenesis of autoimmune disease in general and likely contributes to inflammatory tissue damage and symptoms. Studies focused on identifying autoantibody biomarkers for diagnosis should use targeted data analysis to identify the rarer public epitopes and antigens, common between individuals. Thus, utilisation of human autoantigen profiling technology, combined with different analysis approaches, can illuminate both pathogenesis and biomarker discovery. Springer US 2023-01-24 2023 /pmc/articles/PMC9870766/ /pubmed/36690876 http://dx.doi.org/10.1007/s12026-023-09362-8 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Carlton, Lauren H.
McGregor, Reuben
Moreland, Nicole J.
Human antibody profiling technologies for autoimmune disease
title Human antibody profiling technologies for autoimmune disease
title_full Human antibody profiling technologies for autoimmune disease
title_fullStr Human antibody profiling technologies for autoimmune disease
title_full_unstemmed Human antibody profiling technologies for autoimmune disease
title_short Human antibody profiling technologies for autoimmune disease
title_sort human antibody profiling technologies for autoimmune disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870766/
https://www.ncbi.nlm.nih.gov/pubmed/36690876
http://dx.doi.org/10.1007/s12026-023-09362-8
work_keys_str_mv AT carltonlaurenh humanantibodyprofilingtechnologiesforautoimmunedisease
AT mcgregorreuben humanantibodyprofilingtechnologiesforautoimmunedisease
AT morelandnicolej humanantibodyprofilingtechnologiesforautoimmunedisease